Cimt denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for cimt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies CIMT as Not FDA-Approved — and Why You Can Appeal

Constraint-Induced Movement Therapy (CIMT) is a rehabilitative therapy protocol — not a drug or medical device — and therefore is not subject to FDA approval in the same way that pharmaceuticals or implantable devices are. Cigna's application of a "not FDA-approved" denial basis to CIMT reflects a category mismatch: FDA approval is a regulatory pathway for drugs and devices, not for behavioral or physical rehabilitation protocols.

This is one of the strongest grounds for appeal in the CIMT context. The correct standard for evaluating a rehabilitative therapy is whether it is consistent with "generally accepted standards of medical practice" — the benchmark used in external review under the ACA. CIMT meets that standard: it is endorsed in rehabilitation guidelines from major professional societies including the American Heart Association and American Stroke Association and is widely practiced in accredited rehabilitation centers.

## Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA): File within 180 days of denial. Cigna must respond within 60 days (30 days for pre-service).
• External review (ACA §2719): This denial type is specifically well-suited for external review, because the external reviewer applies the correct legal standard — generally accepted clinical practice — not an FDA-approval test that does not apply to rehabilitative procedures. Request external review within approximately 4 months of the final internal denial.
• Expedited review: Available within 72 hours if clinically urgent.

## What to Gather

1. Clarification of the correct regulatory category: The appeal letter should affirmatively state that CIMT is a rehabilitative therapy protocol, not a drug or device, and that the FDA-approval standard is therefore inapplicable as a coverage criterion. 2. Professional society endorsement: A letter from the treating physiatrist, neurologist, or occupational therapist citing the applicable AHA/ASA stroke rehabilitation guideline recommendation for CIMT — establishing it as a recognized standard of care. 3. Diagnosis and clinical indication: Physician documentation of the diagnosis, onset, upper-limb functional deficits, and the clinical rationale for CIMT. 4. Prior therapy history: Records of prior conventional rehabilitation, establishing that CIMT is the clinically appropriate next step. 5. Cigna's coverage policy language: Request or download the specific policy provision cited in the denial. If it conflates FDA approval with general evidence standards for non-drug services, document that explicitly in the appeal.

## Criteria-Mapping Structure

| Cigna Denial Basis | Appeal Response | |---|---| | "Not FDA-approved" | CIMT is a rehabilitation protocol; FDA approval standard does not apply to therapy protocols | | Not generally accepted clinical practice | AHA/ASA guideline endorsement; widespread clinical use | | Insufficient evidence base | Treating provider attestation of established evidence | | Clinical indication not established | Diagnosis, functional assessment, and prior therapy records |

The external review route is particularly powerful here: independent reviewers are required by law to use the "generally accepted clinical standards" test, which CIMT satisfies — regardless of whether Cigna's internal policy incorrectly applies an FDA-approval framework.